This prompted us to begin a longitudinal assessment of the aPTT, FVIII, fibrinogen, ATIII, and anti-Xa activity in seven patients diagnosed with COVID-19 on CRRT or ECMO and treated with UFH. The gene discussed is TNXA; the disease is COVID-19.